Evidence map›Paper›PMID 26774803›Full record

ArticleBMC infectious diseases2016

High Streptococcus pneumoniae colonization prevalence among HIV-infected Kenyan parents in the year before pneumococcal conjugate vaccine introduction.

Laura M Conklin, Godfrey Bigogo, Geofrey Jagero, Lee Hampton, Muthoni Junghae, Maria da Gloria Carvalho, Fabiana Pimenta, Bernard Beall, Thomas Taylor, Brian Plikaytis and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Intracellular survival ofFrontiers in immunology · 2022
    Article
  6. Article
  7. Article
  8. Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Frontiers in microbiology · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Laura M ConklinDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. dvj3@cdc.gov.
Godfrey BigogoKenya Medical Research Institute/Centers for Disease Control and Prevention, Kisumu, Kenya. gbigogo@kemricdc.org.
Geofrey JageroKenya Medical Research Institute/Centers for Disease Control and Prevention, Kisumu, Kenya. gjagero@icipe.org.
Lee HamptonDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. euf0@cdc.gov.
Muthoni JunghaeKenya Medical Research Institute/Centers for Disease Control and Prevention, Kisumu, Kenya. ivq4@cdc.gov.
Maria da Gloria CarvalhoDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. msc8@cdc.gov.
Fabiana PimentaDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. gzy7@cdc.gov.
Bernard BeallDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. beb0@cdc.gov.
Thomas TaylorDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. tkt1@cdc.gov.
Brian PlikaytisDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. bdplikaytis@gmail.com.
Kayla F LasersonKenya Medical Research Institute/Centers for Disease Control and Prevention, Kisumu, Kenya. kel4@cdc.gov.
John VululeCentre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya. jvulule@kemricdc.org.
Chris Van BenedenDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. cav7@cdc.gov.
Cynthia G WhitneyDivision of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. cgw3@cdc.gov.
Robert F BreimanKenya Medical Research Institute/Centers for Disease Control and Prevention, Kisumu, Kenya. rfbreiman@emory.edu.
Daniel R FeikinKenya Medical Research Institute/Centers for Disease Control and Prevention, Kisumu, Kenya. drf0@cdc.gov.
Centers for Disease Control and Prevention · USKenya Medical Research Institute · KECenters for Disease Control and Prevention · KE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStreptococcus pneumoniae is a leading cause of pneumonia, meningitis and sepsis in developing countries, particularly among children and HIV-infected persons. Pneumococcal oropharyngeal (OP) or nasopharyngeal (NP) colonization is a precursor to development of invasive disease. New conjugate vaccines hold promise for reducing colonization and disease.

methodsPrior to introduction of 10-valent pneumococcal conjugate vaccine (PCV10), we conducted a cross-sectional survey among HIV-infected parents of children <5 years old in rural Kenya. Other parents living with an HIV-infected adult were also enrolled. After broth enrichment, NP and OP swabs were cultured for pneumococcus. Serotypes were identified by Quellung. Antimicrobial susceptibility was performed using broth microdilution.

resultsWe enrolled 973 parents; 549 (56.4%) were HIV-infected, 153 (15.7%) were HIV-uninfected and 271 (27.9%) had unknown HIV status. Among HIV-infected parents, the median age was 32 years (range 15-74) and 374/549 (68%) were mothers. Pneumococci were isolated from 237/549 (43.2%) HIV-infected parents and 41/153 (26.8%) HIV-non-infected parents (p = 0.0003). Colonization with PCV10 serotypes was not significantly more frequent in HIV-infected (12.9%) than HIV-uninfected parents (11.8%; p = 0.70). Among HIV-infected parents, cooking site separate from sleeping area and CD4 count >250 were protective (OR = 0.6; 95% CI 0.4, 0.9 and OR = 0.5; 95% CI 0.2, 0.9, respectively); other associations were not identified. Among 309 isolates tested from all parents, 255 (80.4%) were penicillin non-susceptible (MIC ≥0.12 μg/ml).

conclusionsPrevalence of pneumococcal colonization is high among HIV-infected parents in rural Kenya. If young children are the pneumococcal reservoir for this population, PCV10 introduction may reduce vaccine-type colonization and disease among HIV-infected parents through indirect protection.

Indexed as

AdolescentAdultAgedChildChild, PreschoolCross-Sectional StudiesFemaleHIV InfectionsHumansInfantKenyaMaleMiddle AgedNasopharynxPneumococcal InfectionsPneumococcal Vaccines10-valent pneumococcal conjugate vaccinePneumococcal Vaccines

Identifiers

PMID26774803
PMCPMC4715316
OpenAlexW2266025288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.